Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Disease modifying antirheumatic drugs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Disease modifying antirheumatic drugs. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-002328-42 Sponsor Protocol Number: I1F-MC-RHBE Start Date*: 2015-01-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHBE A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Diseas...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003332-13 Sponsor Protocol Number: M13-549 Start Date*: 2016-01-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) BG (Completed) CZ (Completed) DK (Completed) BE (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) HU (Completed) GR (Completed) AT (Completed) RO (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003335-35 Sponsor Protocol Number: M13-542 Start Date*: 2016-05-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NO (Completed) SK (Completed) PT (Completed) LV (Completed) AT (Completed) FI (Completed) GR (Completed) FR (Completed) BG (Completed) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022242-24 Sponsor Protocol Number: CNTO136ARA3002 Start Date*: 2012-07-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002433-22 Sponsor Protocol Number: I1F-MC-RHBF Start Date*: 2015-11-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study with a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long Term Efficacy and Safety of Ixeki...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) CZ (Completed) GB (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003761-26 Sponsor Protocol Number: CAIN457F2304 Start Date*: 2017-02-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis...
    Medical condition: Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10072745 Enthesitis related arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076674 Juvenile psoriatic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002633-19 Sponsor Protocol Number: RZR12011-TryCort Start Date*: 2011-12-21
    Sponsor Name:Rheumazentrum Ruhrgebiet
    Full Title: Diagnostic value of oral prednisolone test for rheumatoid arthritis
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10062719 Seronegative rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004675-52 Sponsor Protocol Number: I4V-MC-JAHA Start Date*: 2017-07-11
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Art...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Prematurely Ended) HU (Completed) PL (Prematurely Ended) IT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001569-17 Sponsor Protocol Number: ML28699 Start Date*: 2013-08-02
    Sponsor Name:Roche S.p.A.
    Full Title: A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with methotrexate and/or other DMARDS...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001176-10 Sponsor Protocol Number: CNTO136ARA3004 Start Date*: 2013-09-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNT...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) IT (Completed) DE (Prematurely Ended) PT (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) PL (Completed) HR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002324-32 Sponsor Protocol Number: I4V-MC-JADZ Start Date*: 2013-02-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who H...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) GB (Completed) PT (Completed) AT (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000587-17 Sponsor Protocol Number: MA21573 Start Date*: 2008-06-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequat...
    Medical condition: Rheumatoid arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) ES (Completed) FI (Completed) IE (Completed) PT (Completed) CZ (Completed) DK (Completed) FR (Completed) BE (Completed) NL (Completed) HU (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000933-37 Sponsor Protocol Number: M15-925 Start Date*: 2016-11-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Into...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LV (Completed) PT (Completed) SE (Completed) ES (Ongoing) CZ (Completed) BE (Completed) NL (Completed) SK (Prematurely Ended) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002339-27 Sponsor Protocol Number: I4V-MC-JADX Start Date*: 2013-01-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying A...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) IT (Completed) PT (Completed) GB (Completed) CZ (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000431-14 Sponsor Protocol Number: M16-098 Start Date*: 2017-11-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis
    Medical condition: Active Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PT (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004342-14 Sponsor Protocol Number: VX12-509-104 Start Date*: 2013-04-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) EE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000679-35 Sponsor Protocol Number: APHP2000231 Start Date*: 2021-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: SATELITE “Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis”
    Medical condition: Granulomatosis with Polyangiitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003351-37 Sponsor Protocol Number: I4V-MC-JAJA Start Date*: 2019-08-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) HU (Completed) DE (Restarted) GR (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020324-22 Sponsor Protocol Number: CC-10004-PSA-005 Start Date*: 2011-03-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) CZ (Completed) LT (Completed) IT (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003536-23 Sponsor Protocol Number: SFY13370 Start Date*: 2013-02-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) ES (Completed) IT (Completed) SE (Completed) EE (Completed) NO (Completed) FI (Completed) NL (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:13:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA